Thyme Care, Texas Oncology Cut $723K in Pembrolizumab Spending With Weight-Based Dosing
-
At the 2026 ASCO Quality Care Symposium, Thyme Care and Texas Oncology presented results from a weight-based pembrolizumab dosing initiative that reduced care costs by $723,000, a 7.3% reduction compared with projected spending under flat dosing, across roughly 4,500 Texas Oncology patients also covered by plans contracting with Thyme Care.
-
Of 613 pembrolizumab administrations analyzed, 338 were eligible by weight and 115 were switched to weight-based dosing, avoiding 11,800 mg of drug use. Monthly adherence rose after Thyme Care began using payer prior authorization data to build weekly eligibility rosters and routed that data into the pharmacy team’s workflow.
A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and pharmacist workflows to move eligible patients off flat dosing of pembrolizumab.
Pembrolizumab (Keytruda; Merck) is the largest drug line-item in nearly every oncology practice’s budget. The PD-1 inhibitor is also one of the most important therapies ever seen in cancer care, with 44 indications across 19 different cancer types.1 Robert “Bobby” Green, MD, MSCE, president and chief medical officer of Thyme Care, says those 2 facts aren’t in conflict.
“It’s a great drug, right? Just to be clear,” Green said in an interview with The American Journal of Managed Care® (AJMC®). “I’m an oncologist. I saw people who would have died be cured by Keytruda.”
But if there’s a way to reduce a big line item, it makes sense for an oncology practice to do that if it’s safe for patients, especially if the practice might help patients save money, too.
Enter weight-based dosing, a concept that Green and a colleague outlined more than 2 years ago in Evidence-Based Oncology (EBO).2 It’s one that’s worked for Texas Oncology, the largest community oncology practice in the United States.
“This is not [that] we want to limit the use of Keytruda,” Green explained. “But here is a clinically appropriate cost-saving mechanism that you can deploy that can take the highest-cost anticancer drug and reduce the spend of it appreciably.”
At the recent American Society of Clinical Oncology Quality Care Symposium (ASCO Quality) in Boston, Massachusetts, Thyme Care shared results showing how this initiative reduced utilization and cut care costs by $723,000.3That translated into a 7.3% reduction compared with projected spending under flat dosing.3